Play Earnings CallPlay Earnings Call
Zymeworks Inc. (ZYME) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 6:00 PM EST
Company Participants
Kenneth Galbraith – Chairman of the Board, CEO & President
Conference Call Participants
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Presentation
Lut Ming Cheng
JPMorgan Chase & Co, Research Division
Good afternoon. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I’m Brian Cheng. I’m the senior biotech analyst here at the firm. On stage, we have Zymeworks. I will now pass the mic to their CEO, Kenneth Galbraith, for a short presentation, followed by a live audience Q&A. Ken, welcome back. The stage is yours.
Kenneth Galbraith
Chairman of the Board, CEO & President
Great. Thanks very much, Brian. Good afternoon, everyone. I’m really pleased to be back here at JPMorgan this year on a Wednesday afternoon. We really had an amazing transformative year for Zymeworks, including the readout of the HERIZON-GEA-01 study for zanidatamab that happened last week. So from Thursday of last JPMorgan to Wednesday of this JPMorgan, we’ve really just transformed the company and also thought about very carefully how we need to evolve the strategy of the company going forward to build on the success we have so far for just continued success in the company. So I have a very thin slide deck that I’d like to highlight some of the transformations that happened during the past year and maybe some of the highlights of how we’re evolving the strategy to make sure we continue to build shareholder value from this point forward in the company and then open it up to questions from Brian or the crowd. So let’s do that as quickly as I can for you all this afternoon.
Here’s our forward-looking statement, I advise you to
